DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use
Colon cancer remains one of the leading causes of cancer-related deaths worldwide. Transformation of colon epithelial cells into invasive adenocarcinomas has been well known to be due to the accumulation of multiple genetic and epigenetic changes. In the past decade, the etiology of inflammatory bow...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Life |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-1729/11/5/412 |
id |
doaj-d65875368cd84859a47e4a9a259b1900 |
---|---|
record_format |
Article |
spelling |
doaj-d65875368cd84859a47e4a9a259b19002021-04-30T23:04:08ZengMDPI AGLife2075-17292021-04-011141241210.3390/life11050412DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical UseJoo Mi Yi0Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 47392, KoreaColon cancer remains one of the leading causes of cancer-related deaths worldwide. Transformation of colon epithelial cells into invasive adenocarcinomas has been well known to be due to the accumulation of multiple genetic and epigenetic changes. In the past decade, the etiology of inflammatory bowel disease (IBD) which is characterized by chronic inflammation of the intestinal mucosa, was only partially explained by genetic studies providing susceptibility loci, but recently epigenetic studies have provided critical evidences affecting IBD pathogenesis. Over the past decade, A deep understanding of epigenetics along with technological advances have led to identifying numerous genes that are regulated by promoter DNA hypermethylation in colorectal diseases. Recent advances in our understanding of the role of DNA methylation in colorectal diseases could improve a multitude of powerful DNA methylation-based biomarkers, particularly for use as diagnosis, prognosis, and prediction for therapeutic approaches. This review focuses on the emerging potential for translational research of epigenetic alterations into clinical utility as molecular biomarkers. Moreover, this review discusses recent progress regarding the identification of unknown hypermethylated genes in colon cancers and IBD, as well as their possible role in clinical practice, which will have important clinical significance, particularly in the era of the personalized medicine.https://www.mdpi.com/2075-1729/11/5/412epigenetic regulationDNA methylationcolorectal cancerinflammatory bowel diseases (IBDs)biomarkers |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joo Mi Yi |
spellingShingle |
Joo Mi Yi DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use Life epigenetic regulation DNA methylation colorectal cancer inflammatory bowel diseases (IBDs) biomarkers |
author_facet |
Joo Mi Yi |
author_sort |
Joo Mi Yi |
title |
DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use |
title_short |
DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use |
title_full |
DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use |
title_fullStr |
DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use |
title_full_unstemmed |
DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use |
title_sort |
dna methylation change profiling of colorectal disease: screening towards clinical use |
publisher |
MDPI AG |
series |
Life |
issn |
2075-1729 |
publishDate |
2021-04-01 |
description |
Colon cancer remains one of the leading causes of cancer-related deaths worldwide. Transformation of colon epithelial cells into invasive adenocarcinomas has been well known to be due to the accumulation of multiple genetic and epigenetic changes. In the past decade, the etiology of inflammatory bowel disease (IBD) which is characterized by chronic inflammation of the intestinal mucosa, was only partially explained by genetic studies providing susceptibility loci, but recently epigenetic studies have provided critical evidences affecting IBD pathogenesis. Over the past decade, A deep understanding of epigenetics along with technological advances have led to identifying numerous genes that are regulated by promoter DNA hypermethylation in colorectal diseases. Recent advances in our understanding of the role of DNA methylation in colorectal diseases could improve a multitude of powerful DNA methylation-based biomarkers, particularly for use as diagnosis, prognosis, and prediction for therapeutic approaches. This review focuses on the emerging potential for translational research of epigenetic alterations into clinical utility as molecular biomarkers. Moreover, this review discusses recent progress regarding the identification of unknown hypermethylated genes in colon cancers and IBD, as well as their possible role in clinical practice, which will have important clinical significance, particularly in the era of the personalized medicine. |
topic |
epigenetic regulation DNA methylation colorectal cancer inflammatory bowel diseases (IBDs) biomarkers |
url |
https://www.mdpi.com/2075-1729/11/5/412 |
work_keys_str_mv |
AT joomiyi dnamethylationchangeprofilingofcolorectaldiseasescreeningtowardsclinicaluse |
_version_ |
1721497210409975808 |